What ChondroFiller is and who it suits

Whether ChondroFiller™ Liquid is relevant to your knee depends on the nature of the damage, not simply on how much pain you are in. It is designed for focal articular cartilage defects — discrete, contained areas of chondral damage — rather than the widespread joint-surface loss associated with generalised osteoarthritis. If MRI confirms a specific lesion, often resulting from a sporting injury, osteochondritis dissecans, or prolonged wear at a single site, it may be worth considering. If the cartilage loss is diffuse and affects multiple compartments throughout the knee, the treatment may be less appropriate.

ChondroFiller™ Liquid is a CE-marked Class III medical device — the highest regulatory tier for implantable medical products in Europe — manufactured as an injectable collagen scaffold. It is not a painkiller, not a lubricating injection, and not a corticosteroid. Its role is to support the body's own repair processes within a focal defect, providing a structural environment that the surrounding tissue can work with over time.

The injection pathway carries no published upper age limit; suitability is assessed on defect size and joint condition, not on age alone. No GP referral is required to book an initial assessment. This is a private, self-funded treatment — there is currently no NHS commissioning pathway for ChondroFiller in the UK.

How it differs from a standard knee injection

Once the collagen hydrogel enters the cartilage defect under ultrasound guidance, it self-gels within minutes, forming a stable three-dimensional structure that fills the lesion. This is the starting point for a process called acellular matrix-induced chondrogenesis — in plain terms, the scaffold draws in the patient's own repair cells rather than containing any donor cells itself.

Those cells — progenitor cells from the surrounding synovium and subchondral bone — migrate into the scaffold, receive chemical signals from the collagen matrix, and gradually differentiate into chondrocytes, promoting endogenous repair within the focal defect. Over months, as new cartilage-like tissue matures, the scaffold resorbs naturally and is replaced by the patient's own tissue. This is not an instant effect; MRI evidence suggests the scaffold continues to mature well into the first year following injection.

Hyaluronic acid (HA) injections work through an entirely different mechanism. HA is a lubricating molecule that supplements the knee's natural synovial fluid, reducing friction and easing symptoms for roughly three to six months before the effect diminishes and another cycle is needed. That is a legitimate palliative role — particularly for patients with widespread joint discomfort — but HA does not scaffold a focal defect or recruit repair cells.

HA has a legitimate role in managing day-to-day joint discomfort; ChondroFiller™ targets the defect itself. Whether a repair strategy or symptom management is the more relevant starting point is largely determined by what the MRI shows and confirmed through a specialist assessment.

What it costs in the UK

Pricing follows a transparent, defect-size tier structure that is consistent across UK private clinics as of 2026. The guide costs are:

• One cartilage unit (~3 cm²): £3,000
• Two units (~4.5 cm²): £5,500
• Three units (~6 cm²): £8,000
• Complex or multi-compartmental Grade III/IV presentations: up to £9,800

The final tier can only be confirmed after an MRI review that establishes the exact defect size, so the figures above should be treated as guide costs rather than guaranteed quotes — verify the applicable price with the treating clinic before booking.

These fees operate on a bundled model. A single invoice covers the pre-injection consultation, imaging review, real-time ultrasound guidance, the ChondroFiller™ product, intravenous antibiotic cover, and a six-week follow-up appointment. No separate theatre, anaesthetist, or physiotherapy invoices are documented.

As noted earlier, this is a self-funded private treatment. Private medical insurers do not routinely cover ChondroFiller™; patients who hold a PMI policy should check the terms in writing before committing.

How it compares with surgical alternatives

For context, private knee cartilage surgery generally costs between £7,000 and £14,000, and MACI — a cell-based cartilage restoration procedure — is typically £30,000–£40,000 or more privately. Microfracture can appear cheaper at £4,500–£7,000 but produces structurally inferior fibrocartilage and carries a higher reoperation rate. MACI holds NICE approval and may be accessible through the NHS for eligible patients — a meaningful funding difference worth exploring if surgical intervention is under consideration. ChondroFiller™ injection sits below most surgical options in cost while avoiding the recovery demands of a theatre procedure.

Getting access without a GP referral

For patients outside London, the Lincolnshire Knee Clinic — part of the MSK Doctors group — offers consultant-led ChondroFiller™ assessments at outpatient sites in Sleaford and Grantham, with no NHS-style waiting list and no referral letter required. London-based patients are seen at the London Cartilage Clinic, 66 Harley Street, which was the first UK clinic to offer ChondroFiller® as an outpatient injection.

The pathway from first contact to injection day is straightforward. An initial suitability consultation reviews existing MRI imaging where available; if no recent scan exists, imaging can be arranged — Lincolnshire Knee has an onsite Open MRI at its Sleaford site. Once defect size and location are confirmed, the clinician can advise on the applicable price tier and whether the injection pathway or a surgical alternative is the more appropriate route for that particular presentation.

The injection itself is an outpatient appointment. No general anaesthetic is involved, there is no theatre admission, and patients do not stay overnight. The treatment is delivered under ultrasound guidance in a clinic setting.

Before a first assessment, it is worth gathering any recent MRI reports and imaging discs, a summary of how long symptoms have been present, and a note of previous treatments already tried. Bringing this information allows the consulting clinician to focus the appointment on the clinical decision points that matter most — particularly defect characteristics and whether suitability criteria are met — rather than reconstructing history from scratch.

What happens on the day and in the weeks after

On the day of the appointment, the injection is delivered under real-time ultrasound guidance in an outpatient clinic setting. There is no sedation or general anaesthetic; the image-guided placement takes a matter of minutes, intravenous antibiotic cover is given as a precautionary measure within the bundled pathway, and patients leave the clinic the same day. There is no theatre admission, no overnight stay, and no surgical wound to manage.

What follows is where patient expectations matter most. As the repair process described earlier takes hold — the scaffold populating with the body's own cells over a period of weeks — improvement is gradual rather than immediate. This is not a steroid or hyaluronic acid injection; there is no short-term analgesic or lubricating effect to draw on in the first days after treatment.

MRI evidence illustrates the timeline well. MOCART defect-filling scores in European studies progressed from around 65 at four weeks to 81.6 at twelve months, reflecting progressive scaffold maturation rather than a rapid result. Clinically, IKDC functional scores show meaningful improvement across the same twelve-month window — in the Jerosch et al. prospective PMCF study, the mean gain of 32.4 points was sustained and slightly increased at three-year follow-up, with patients reaching an average functional score of 80.

Patients should plan their expectations around a months-long repair arc. The six-week follow-up included in the bundled fee provides an early clinical checkpoint, but the fuller benefit typically emerges over the course of the first year.

What the clinical evidence shows and where gaps remain

The gains described in the preceding section come from a prospective post-market clinical follow-up (PMCF) study led by Jerosch et al. — the strongest available evidence horizon for ChondroFiller™ in the knee. To contextualise those figures: the minimum clinically important difference (MCID) on the IKDC functional scale is 16.7 points — the threshold at which patients perceive a meaningful change. The improvement recorded in that cohort more than doubles that benchmark, and the effect was maintained, and slightly increased, at three-year review. European MRI follow-up confirmed structural defect integration rather than surface-level filling alone.

That is where the evidence currently sits, and the limitations deserve equal weight.

No published randomised controlled trial has directly compared ChondroFiller™ against hyaluronic acid viscosupplementation or microfracture in a UK patient cohort. The available evidence is observational and post-market in design — clinically informative, but not the same standard as a head-to-head trial. Long-term outcome data beyond three years in real-world UK populations have not yet been published; whether scaffold-induced repair maintains structural integrity at five or ten years remains an open question.

Patient selection also defines the evidence base. Every published study targets focal, discrete cartilage defects rather than diffuse or whole-joint osteoarthritis, and outcomes from that specific context cannot be assumed to extend to generalised joint degeneration. A pre-treatment MRI review exists precisely to establish whether a presentation falls within that evidence-supported indication.

1. [1] Ultramodern natural and synthetic polymer hydrogel scaffolds for articular cartilage repair and regeneration. (2025). https://doi.org/10.1186/s12938-025-01342-3 https://doi.org/10.1186/s12938-025-01342-3